Challenges and pitfalls of combining targeted agents in phase I studies

被引：43

作者：

Cannistra, Stephen A. ^{[1
]}

机构：

[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 22期

关键词：

D O I：

10.1200/JCO.2008.17.2676

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3665 / 3667

页数：3

共 18 条

[1]

Azad NS, 2007, J CLIN ONCOL, V25

[2] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].

Azad, Nilofer S. ;

Posadas, Edwin M. ;

Kwitkowski, Virginia E. ;

Steinberg, Seth M. ;

Jain, Lokesh ;

Annunziata, Christina M. ;

Minasian, Lori ;

Sarosy, Gisele ;

Kotz, Herbert L. ;

Premkumar, Ahalya ;

Cao, Liang ;

McNally, Deborah ;

Chow, Catherine ;

Chen, Helen X. ;

Wright, John J. ;

Kohn, Elise C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714

[3] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].

Burger, Robert A. ;

Sill, Michael W. ;

Monk, Bradley J. ;

Greer, Benjamin E. ;

Sorosky, Joel I. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171

[4] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [J].

Cannistra, Stephen A. ;

Matulonis, Ursula A. ;

Penson, Richard T. ;

Hambleton, Julie ;

Dupont, Jakob ;

Mackey, Howard ;

Douglas, Jeffrey ;

Burger, Robert A. ;

Armstrong, Deborah ;

Wenham, Robert ;

McGuire, William .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5180-5186

[5] Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models [J].

Chang, Yong S. ;

Adnane, Jalila ;

Trail, Pamela A. ;

Levy, Joan ;

Henderson, Arris ;

Xue, Dahai ;

Bortolon, Elizabeth ;

Ichetovkin, Marina ;

Chen, Charles ;

McNabola, Angela ;

Wilkie, Dean ;

Carter, Christopher A. ;

Taylor, Ian C. A. ;

Lynch, Mark ;

Wilhelm, Scott .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) :561-574

[6] Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors [J].

Clark, JW ;

Eder, JP ;

Ryan, D ;

Lathia, C ;

Lenz, HJ .

CLINICAL CANCER RESEARCH, 2005, 11 (15) :5472-5480

[7] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[8] Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22 [J].

Fisher, B ;

Anderson, S ;

Wickerham, DL ;

DeCillis, A ;

Dimitrov, N ;

Mamounas, E ;

Wolmark, N ;

Pugh, R ;

Atkins, JN ;

Meyers, FJ ;

Abramson, N ;

Wolter, J ;

Bornstein, RS ;

Levy, L ;

Romond, EH ;

Caggiano, V ;

Grimaldi, M ;

Jochimsen, P ;

Deckers, P .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1858-1869

[9]

Giantonio BJ, 2006, J CLIN ONCOL, V24, p155S

[10] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

← 1 2 →